15th International Conference on Parkinson’s and Alzheimer’s Diseases
date
March 9-14, 2021location
VirtualThe 15th International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, AD/PD™ 2021, will build on the well-earned reputation of the groundbreaking series of Alzheimer’s and Parkinson’s Diseases Conferences, which attract international medical and scientific professionals worldwide.
In light of the continuing uncertainty about the evolution of the COVID-19 pandemic and its impact on travel restrictions and physical distancing requirements throughout 2021, the AD/PD™ Organizing Committee has decided to transform this COVID crisis into a new opportunity and will hold the AD/PD™ 2021 conference as a fully online, virtual experience.
Quanterix will be sponsoring this important event with a virtual booth and lobby video.
Poster presentations featuring research facilitated by Simoa technology:
P220 / #1487 J. Kaplow, et al
Theme A: ß-Amyloid Diseases / A4.c. Imaging, Biomarkers, Diagnostics: PET – amyloid
PERFORMANCE OF CSF AD BIOMARKERS IN PREDICTING AMYLOID PET POSITIVITY IN EARLY AD: DATA FROM EISAI’S MISSIONAD PROGRAM
P232 / #566 D. Alcolea, et al
Theme A: β-Amyloid Diseases / A4.h. Imaging, Biomarkers, Diagnostics: CSF, blood, body fluid biomarkers
PLASMA BIOMARKERS IN THE AT(N) CATEGORIES FOR THE DETECTION OF ALZHEIMER’S DISEASE
P233 / #1264 E. Andersson, et al
Theme A: β-Amyloid Diseases / A4.h. Imaging, Biomarkers, Diagnostics: CSF, blood, body fluid biomarkers
CEREBROSPINAL FLUID AΒ42 AND AΒ40 AND THEIR RELATION TO SOLUBLE AND INSOLUBLE AΒ IN THE BRAIN IN ALZHEIMER’S DISEASE
P245 / #1259 A. Moscoso, et al
Theme A: β-Amyloid Diseases / A4.h. Imaging, Biomarkers, Diagnostics: CSF, blood, body fluid biomarkers
ASSOCIATION OF BLOOD PHOSPHORYLATED TAU181 AND NEUROFILAMENT LIGHT WITH PROGRESSIVE NEURODEGENERATION IN ALZHEIMER DISEASE
P254 / #1287 C. Rubel, et al
Theme A: β-Amyloid Diseases / A4.h. Imaging, Biomarkers, Diagnostics: CSF, blood, body fluid biomarkers
CROSS-PLATFORM EVALUATION OF HIGHLY SENSITIVE IMMUNOASSAY TECHNOLOGIES FOR SERUM MEASURES OF PTAU181: PERFORMANCE IN ALZHEIMER’S DISEASE
P255 / #1284 J. Simrén, et al
Theme A: β-Amyloid Diseases / A4.h. Imaging, Biomarkers, Diagnostics: CSF, blood, body fluid biomarkers
ALTERNATIVE PROTOCOLS TO SUPPORT BLOOD COLLECTION IN CHALLENGING PRE-ANALYTICAL CONDITIONS
P302 / #1436 C. Johansson, et al
Theme A: β-Amyloid Diseases / A6.a. Cell, Molecular and Systems Biology: APP, APLP, Abeta DIFFERENTIAL PLASMA BIOMARKER PROFILE IN FAMILIAL ALZHEIMER DISEASE
P384 / #934 K. Foster, et al
Theme B: Taupathies / B2.b. Therapeutic Targets, Mechanisms for Treatment: Immunotherapy
EVALUATION OF PNT001, A MONOCLONAL ANTIBODY DIRECTED TOWARD CIS-PT231 TAU, IN HUMAN TISSUE AND THE TG4510 TAU TRANSGENIC MOUSE
P391 / #659 T. Miyasaka, et al
Theme B: Taupathies / B2.m. Therapeutic Targets, Mechanisms for Treatment: Other
THE EXPRESSION OF MICROTUBULE ASSOCIATED PROTEIN TAU IN MICE PODOCYTE.
P538 / #1227 S. Canaslan, et al
Theme C: α-Synucleinopathies / C4.f. Imaging, Biomarkers, Diagnostics: CSF, blood, body fluid biomarkers
DETECTION OF DIAGNOSTIC RELEVANT BIOMARKER PROTEINS IN PLASMA AND CSF OF ALPHA SYNUCLEINOPATHIES BY SINGLE MOLECULE ARRAY (SIMOA)
P369 / #683 N. Zhu, et al
Theme B: Taupathies / B1.j. Disease Mechanisms, Pathophysiology: Astroglia
PLASMA GLIAL FIBRILLARY ACIDIC PROTEIN AND NEUROFILAMENT, AND THEIR COMBINATION AS BIOMARKERS IN FRONTOTEMPORAL DEMENTIA
P240 / #893 M. Grothe, et al
Theme A: β-Amyloid Diseases / A4.h. Imaging, Biomarkers, Diagnostics: CSF, blood, body fluid biomarkers
NEUROPATHOLOGIC CORRELATES OF ELECSYS-DERIVED CEREBROSPINAL FLUID BIOMARKERS OF ALZHEIMER’S DISEASE IN COMPARISON TO A NOVEL PLASMA-BASED P-TAU181 BIOMARKER
P482 / #1461 A. Pilotto, et al
Theme C: α-Synucleinopathies / C1.p. Disease Mechanisms, Pathophysiology: Modeling of disease progression
PLASMA INFLAMMATORY AND NEURODEGENERATION MARKERS AND DISEASE PROGRESSION IN LEWY BODIES DISORDERS
P540 / #417 K. Fraser, et al
Theme C: α-Synucleinopathies / C4.f. Imaging, Biomarkers, Diagnostics: CSF, blood, body fluid biomarkers
EVALUATING SERUM NEUROFILAMENT LIGHT AS A MEASURE OF TREATMENT RESPONSE IN STANDARD SIZED PH2 PARKINSON’S DISEASE TRIALS
Poster presentation featuring research performed using the Uman NF-Light™ Assay:
P545 / #175 E. Papuć, et al
Theme C: α-Synucleinopathies / C4.f. Imaging, Biomarkers, Diagnostics: CSF, blood, body fluid biomarkers
INCREASED CSF NFL IN NON-DEMENTED PARKINSON’S DISEASE PATIENTS REFLECTS EARLY WHITE MATTER DAMAGE
View Full Abstract Book